PD is a progressive neurodegenerative disorder affecting an estimated 78,000 Australians. Predominantly it affects older people, although or younger. Medications to treat PD are aimed at controlling symptoms as there is no known cure. A regime of PD medications may involve taking doses at frequent intervals and adverse reactions are common. Education of the person with PD, their close carers and family that covers medications, observational techniques and dealing with side effects, along with unpredictable worsening of PD symptoms, may result in improvement in quality of life. When the person with PD has realistic expectations about PD drug therapy then the ability to cope with the physical disability caused by symptoms may be improved. It is important to educate about any possible interaction with commonly taken drugs including dietary supplements and over-the-counter medication. Before a medication education session, nurse activities should include assessment of the person with PD and their support network, development of an appropriate education plan and subsequent implementation, followed by evaluation. Ongoing nursing support at each clinic visit can provide opportunity for evaluation. An individualised session guided by the principles of adult learning theory may provide a successful tool for use in the education of people with PD as well as healthcare professionals. A large amount of available information and untested educational material does not address the educational needs of people with PD with regard to their medications. There is a need for further research in this area. The effectiveness of a one-on-one educational session about PD medication supported by printed, individualised PD medication information may provide more appropriate education and lead to improved quality of life. It is the focus of a planned research study.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.7748/nop2005.03.17.1.14.c2357 | DOI Listing |
Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to amyloid-beta (Aβ) protofibrils, was formally evaluated as a treatment for early Alzheimer's disease in a phase 2 study (Study 201) and the phase 3 Clarity AD study. These trials both included an 18-month, randomized study (core) and an open-label extension (OLE) phase where eligible participants received open-label lecanemab for up to 30 months to date. Clinical (CDR-SB, ADAS-Cog14, and ADCS-MCI-ADL), biomarker (PET, Aβ42/40 ratio, and ptau181) and safety outcomes were evaluated.
View Article and Find Full Text PDFAlzheimer's disease pathophysiology is believed to involve various abnormalities, including those of amyloid beta (Ab) peptide and tau processing, inflammation, oxidative stress, and vascular risk factors. Aβ peptides exist in a dynamic continuum of conformational states from monomeric Aβ, to soluble progressively larger Aβ assemblies that include a range of low molecular weight oligomers to higher molecular weight protofibrils, and finally to insoluble fibrils (plaques). Various lines of evidence support the "amyloid hypothesis" that Aβ plays a central role in the pathogenesis of AD, and several immunotherapies have been developed to interact with this cascade in various different places which may reduce the number of soluble aggregates and insoluble Aβ fibrils deposited in the brain.
View Article and Find Full Text PDFBackground: Lecanemab is an approved anti-amyloid monoclonal antibody that binds with highest affinity to soluble Aβ protofibrils, which are more toxic than monomers or insoluble fibrils/plaque. In clinical studies, biweekly lecanemab treatment demonstrated a slowing of decline in clinical (global, cognitive, functional, and quality of life) outcomes, and reduction in brain amyloid in early Alzheimer's disease (AD). Herein, we describe the impact of lecanemab treatment on tau PET.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Stevenson University, Owings Mills, MD, USA.
Background: Most assisted living (AL) settings organize and provide opportunities for residents to participate in activities (e.g., exercise, music, arts and craft, cognitive activities, religious services, community outings).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University College London, London, United Kingdom.
Background: The progressive nature of dementia and the complex needs means that people living with dementia require tailored approaches to address their changing care needs over time. These include physical multimorbidity, psychological, behavioural, and cognitive symptoms and possible risks arising from these and helping family caregivers. However, provision of these interventions is highly variable between and within countries, partly due to uncertainty about their efficacy and scarce resources.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!